TickerTalks
Browse all tickers →
TickerTalks›$SCTX
SCSCTX

Scribe Therapeutics Inc.

$SCTX·$421M·Biotechnology·Healthcare
$30.54+7.4%1Y+103.6%
Mentions · last 7 days
2026-08-22: 4 posts48+9%
Price updated 5h ago·X counts updated 9d ago
SCSCTX
$SCTXScribe Therapeutics Inc.
$30.54+7.38%48 posts+9%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $SCTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellStalledAI verdict · as of 2026-08-26

The move has stalled — likely just drifts unless something new shows up.

Scribe Therapeutics is a fresh IPO with LLY and SNY as anchor investors — $155.5M raised, but today's -16% pullback signals early volatility.

Scribe Therapeutics Inc. is a fresh-IPO CRISPR-based therapeutics developer backed by Lilly and Sanofi with a concurrent private placement. The equity is too-early with limited operating history but a substantial funding footprint.

  • The IPO structure is unusually well-funded: upsized IPO and concurrent Sanofi private placement raising ~$155.5M gross (9.867M shares at $15 plus a Sanofi purchase) — that's an unusually large fresh capital raise for a CRISPR-therapeutic name at IPO, and Behzad Aghazadeh's $36.12M July 24 insider buy plus OrbiMed and Director $15M and 10% owner AH Bio $5M add to the institutional-conviction stack.
  • The financials are pre-clinical: sell-side estimates for Sept 2 quarterly print at -$2.97 EPS — that's a burn-rate estimate for a pre-scale biotech; no revenue, no pipeline milestones in the near-term public calendar, so the equity is essentially a call option on future clinical execution.
  • The tape is limited: no 52-week range percentile available (fresh IPO), today's -16.2% pullback on the IPO trading day is normal price discovery for a new listing with limited history; the LLY/SNY anchor investors provide floor support.

The path if this works is a specific preclinical or partnership-milestone announcement plus the Sept 2 quarterly print showing cash-runway detail, taking the tape past $40. What breaks it is another dilutive raise or a specific pipeline setback — SCTX is a fresh-IPO biotech with no fundamental cushion, so any operational execution issue compresses the multiple hard.

What to watch: Sept 2 quarterly print (sell-side EPS -$2.97) — cash-runway detail plus any specific pipeline-milestone or partnership announcement extends the tape past $40; another dilutive raise or a pipeline setback breaks the tape back to $20.

On the calendar: 2026-09-02 — first quarterly earnings

thin bundle

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-08-04

Scribe Therapeutics posters are running a fresh-IPO conviction thread. SCTX is Nasdaq-listed backed by LLY and SNY, closed an upsized IPO and concurrent Sanofi private placement raising ~$155.5M gross (9.867M shares at $15 plus a Sanofi purchase). Insider Form 4 activity shows Behzad Aghazadeh buying $36.12M on July 24, plus Orbimed and Director both $15M and 10% owner AH Bio $5M. Little bearish voice; the tone is 'follow the money.'

Read the AI verdict + X sentiment for $SCTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage CRISPR gene editing company engineering proprietary in vivo delivery tools for genetic disease treatments.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $SCTX.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $SCTX

Neutral — Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-b; exposure to the industry macro driver is limited or indirect.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Next earningsWed, Sep 2·consensus EPS $-3.62

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13DActivist position (5%+)Jul 30SC 13D
AI summary

Avoro Capital Advisors LLC, Avoro Ventures LLC, and controlling person Behzad Aghazadeh filed an initial Schedule 13D for Scribe Therapeutics, Inc. (SCTX) following its July 2026 IPO. Avoro Capital Advisors holds 2,598,973 shares (13.78%), Avoro Ventures holds approximately 490,915 shares (2.60%), and Aghazadeh's aggregate beneficial ownership is 3,088,888 shares (16.37%). Dr. Aghazadeh serves on the SCTX board of directors; the group is classified as activist investors (Schedule 13D vs. 13G). This is a significant ownership position for a newly public CRISPR gene editing company at IPO, with Avoro being an active healthcare investor.

SC 13DActivist position (5%+)Jul 30SC 13D
AI summary

Eli Lilly and Company filed a Schedule 13D for Scribe Therapeutics, Inc. (SCTX) disclosing 1,388,161 shares = 7.3% of post-IPO outstanding shares, acquired using working capital following the July 2026 IPO. This is a strategic investment by a global pharmaceutical leader in a CRISPR gene-editing platform company co-founded by CRISPR pioneer Jennifer Doudna. A Schedule 13D (vs. 13G) indicates Lilly may seek to influence the company's direction, though its specific investment intent is not disclosed in this excerpt.

SC 13DActivist position (5%+)Jul 29SC 13D
AI summary

OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC (investment advisory firm) filed a Schedule 13D for Scribe Therapeutics, Inc. (SCTX) disclosing 1,348,825 shares = approximately 7.2% of post-IPO outstanding shares held through OrbiMed Private Investments VIII LP. Board representative Carl Gordon is a member of OrbiMed's management committee. OrbiMed's 7.2% position, combined with board representation, reflects a lead institutional investor in SCTX's pre-IPO preferred rounds maintaining a significant post-IPO stake.

8-KCharter amendmentJul 278-K — Item 5.03: Charter amendment
AI summary

Scribe Therapeutics Inc. (SCTX) filed an 8-K disclosing the adoption of its Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Amended and Restated Bylaws (Exhibit 3.2), both effective immediately prior to the closing of its IPO. These charter documents were previously approved by the board and stockholders in connection with the IPO process. This is a routine governance filing accompanying Scribe Therapeutics' initial public offering.

424B4Prospectus supplement (offering)Jul 27424B4
AI summary

Scribe Therapeutics Inc. (SCTX) completed its initial public offering on or about July 27, 2026, offering 8,580,000 shares at $15.00 per share for gross proceeds of $128.7 million ($119.7M to the company after $9.0M in underwriting discounts). An additional 1,287,000 shares are available via overallotment option for 30 days. Sanofi/Aventis separately purchased 500,000 shares in a concurrent private placement at $15.00/share. Underwriters: Leerink Partners, Goldman Sachs, Guggenheim Securities, Wells Fargo. Scribe is listed on Nasdaq under 'SCTX' and is a CRISPR/base-editing company co-founded by Jennifer Doudna.

3New insider — initial holdingsJul 233
AI summary

Eli Lilly and Company filed a Form 3 for Scribe Therapeutics, Inc. (SCTX) reflecting its pre-IPO status as a 10% or greater beneficial owner, noting that after the IPO closes Lilly's ownership will fall below 10% and it will have no further Section 16 reporting obligations. Filed via Lilly's VP/Corporate Secretary. This is a transitional insider ownership disclosure at the time of SCTX's IPO where Lilly converts from a pre-IPO 10%+ holder to a sub-10% strategic investor.

3New insider — initial holdingsJul 233
AI summary

OrbiMed Private Investments VIII, LP (through GP OrbiMed Capital GP VIII LLC and managing member OrbiMed Advisors LLC) filed a Form 3 for Scribe Therapeutics, Inc. (SCTX). OrbiMed holds Series B Preferred Stock convertible into common stock; Carl Gordon serves as Scribe's board representative from OrbiMed. Voting and investment power rests with Gordon, Sven Borho, and W. Carter Neild. This is an initial insider ownership statement for OrbiMed as a 10%+ holder at IPO.

3New insider — initial holdingsJul 233
AI summary

Andreessen Horowitz (a16z), through AH Bio Fund III, LP and AH Equity Partners Bio III, LLC, filed a Form 3 for Scribe Therapeutics, Inc. (SCTX) with Marc Andreessen and Ben Horowitz as the reporting persons, both as 10%+ owners and directors. This is a combined filing for the a16z healthcare venture fund's SCTX pre-IPO ownership position. The filing reflects Andreessen Horowitz as a lead pre-IPO institutional backer and ongoing board presence at the newly public SCTX.

+ 20 other (9 3s · 2 S-1/As · 2 DRS/As · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More247wallst.com·18h agoScribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placementglobenewswire.com·35d agoScribe Therapeutics Announces Pricing of Upsized Initial Public Offeringglobenewswire.com·39d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · last 7 days

No standout posts about $SCTX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport